Nektar Therapeutics Announces Two Abstracts Accepted At EADV Congress 2023 For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy

Press/Media

Period2 Oct 2023

Media coverage

47

Media coverage